Search
for
Sort by
Research 61–90 of 1000+
- Comprehensive Study of Drug-Induced Pruritus Based on Adverse Drug Reaction Report Database
- 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
- Medications affecting the insulin-like growth factor 1/growth hormone axis, including teprotumumab, somatostatin analogs, and anti-calcitonin gene-related peptide monoclonal antibodies, are associated with elevated reporting odds of alopecia in women: A pharmacovigilance study
- Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- Finasteride toxicity information: “limited”, “poor quality”, “biased”
- 0348 Adverse event reports of alopecia for sunscreen ingredients and branded products
- Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
- Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017
- Signal Detection for Adverse Events of Finasteride Using Korea Adverse Event Reporting System (KAERS) Database
- Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
- PD29-07 DRUGS ASSOCIATED THE MOST WITH MALE-FACTOR INFERTILITY: ASSESSMENT OF THE 2010-2020 FOOD AND DRUG ADMINISTRATION (FDA) PHARMACOVIGILANCE DATABASE
- The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis
- Reporting on Adverse Clinical Events
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- PD49-02 MEDICATIONS MOST COMMONLY ASSOCIATED WITH ERECTILE DYSFUNCTION: EVALUATION OF THE FOOD AND DRUG ADMINISTRATION NATIONAL PHARMACOVIGILANCE DATABASE
- Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis
- Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network
- Faculty Opinions recommendation of Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
- Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation
- Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
- Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
- Dermatologic Adverse Events from Cancer Treatments
- Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
- Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
- Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series
- Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review
- Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?